Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A phase 3 randomized, masked, placebo-controlled Apricity clinical trial assessing EpiSmart for the treatment of keratoconus

Next Previous
X
Search
Trial Profile

A phase 3 randomized, masked, placebo-controlled Apricity clinical trial assessing EpiSmart for the treatment of keratoconus

Status: Planning
Phase of Trial: Phase III

Latest Information Update: 02 Nov 2023

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Riboflavin (Primary)
  • Indications Keratoconus
  • Focus Adverse reactions; Registrational; Therapeutic Use
  • Sponsors Epion Therapeutics

    • Most Recent Events

    • 31 Oct 2023 According to an Epion Therapeutics media release, company announced the commencement of Phase 3 Apricity trials for EpiSmart, the companys minimally-invasive keratoconus therapy. The company plans to enroll 800 subjects at over 20 investigational sites throughout the US in two concurrent Apricity Phase 3 trials.
    • 10 Oct 2022 New trial record
    • 30 Sep 2022 According to CXL Ophthalmics media release, the company has raised a $32 million Series A funding round led by AXA IM Alts through its Global Health Private Equity strategy plus a syndicate of individual investors, including leading cornea specialists. The new investments will support the advancement of CXL Ophthalmics (CXLO) transformative cross-linking system, EpiSmart, through Phase 3 trials on the way to a New Drug Application with FDA.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top